Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 07  •  04:00PM ET
7.26
Dollar change
-0.21
Percentage change
-2.81
%
IndexRUT P/E- EPS (ttm)-2.24 Insider Own37.63% Shs Outstand35.85M Perf Week-4.10%
Market Cap260.31M Forward P/E- EPS next Y-2.84 Insider Trans0.00% Shs Float22.36M Perf Month33.21%
Enterprise Value-28.24M PEG- EPS next Q-0.76 Inst Own33.98% Short Float3.10% Perf Quarter67.28%
Income-79.03M P/S67.44 EPS this Y65.60% Inst Trans2.48% Short Ratio2.16 Perf Half Y79.70%
Sales3.86M P/B0.88 EPS next Y-24.72% ROA-32.48% Short Interest0.69M Perf YTD25.39%
Book/sh8.22 P/C0.88 EPS next 5Y23.58% ROE-35.88% 52W High22.92 -68.33% Perf Year-66.89%
Cash/sh8.29 P/FCF- EPS past 3/5Y-30.62% - ROIC-26.58% 52W Low2.88 152.08% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin95.34% Volatility6.93% 6.67% Perf 5Y-
Dividend TTM- EV/Sales-7.32 EPS Y/Y TTM- Oper. Margin-2364.20% ATR (14)0.50 Perf 10Y-
Dividend Ex-Date- Quick Ratio13.21 Sales Y/Y TTM- Profit Margin-2045.74% RSI (14)60.91 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio13.21 EPS Q/Q-51.32% SMA207.66% Beta1.86 Target Price9.67
Payout- Debt/Eq0.03 Sales Q/Q- SMA5024.94% Rel Volume1.51 Prev Close7.47
Employees64 LT Debt/Eq0.01 EarningsNov 06 AMC SMA20055.36% Avg Volume320.88K Price7.26
IPOSep 26, 2024 Option/ShortYes / Yes EPS/Sales Surpr.4.04% 164.18% Trades Volume485,012 Change-2.81%
Date Action Analyst Rating Change Price Target Change
Oct-22-25Upgrade Citigroup Neutral → Buy $10
Feb-28-25Initiated William Blair Mkt Perform
Dec-10-24Downgrade Morgan Stanley Overweight → Underweight $40 → $5
Dec-09-24Downgrade Jefferies Buy → Hold $42 → $7
Dec-09-24Downgrade Citigroup Buy → Neutral $45 → $7
Oct-21-24Initiated Morgan Stanley Overweight $40
Oct-21-24Initiated Jefferies Buy $42
Oct-21-24Initiated Citigroup Buy $45
Nov-07-25 09:00AM
Nov-06-25 04:45PM
Nov-05-25 07:45AM
Oct-29-25 06:15AM
Oct-26-25 06:33PM
07:36AM Loading…
Oct-23-25 07:36AM
Aug-20-25 04:30PM
Aug-18-25 07:36AM
Aug-15-25 09:00AM
Aug-06-25 04:30PM
Jul-29-25 10:23AM
Jun-21-25 06:00PM
Jun-17-25 09:00AM
Jun-03-25 09:00AM
May-30-25 09:05AM
11:18PM Loading…
May-29-25 11:18PM
09:00AM
May-27-25 04:30PM
May-06-25 04:30PM
Apr-21-25 01:02PM
Mar-22-25 11:00AM
Mar-20-25 04:30PM
Mar-17-25 01:54PM
Mar-04-25 05:07AM
Feb-20-25 04:30PM
10:36AM
Feb-16-25 07:18AM
Feb-14-25 05:45AM
Feb-13-25 08:42AM
Feb-07-25 05:45AM
09:01AM Loading…
Jan-30-25 09:01AM
Jan-29-25 05:39AM
Jan-28-25 07:27PM
09:00AM
Jan-24-25 05:45AM
Jan-22-25 03:00AM
Jan-21-25 05:45AM
Jan-18-25 03:07AM
Jan-06-25 09:00PM
Jan-03-25 12:51PM
Jan-02-25 09:35AM
Jan-01-25 05:00AM
Dec-27-24 11:32AM
09:18AM
Dec-26-24 07:23AM
Dec-25-24 07:04AM
Dec-23-24 10:19AM
Dec-19-24 01:15PM
05:46AM
Dec-18-24 09:00AM
Dec-16-24 04:20PM
03:00AM
Dec-13-24 10:31AM
Dec-12-24 06:34PM
Dec-09-24 07:51PM
09:28AM
07:41AM
Dec-07-24 06:34AM
Dec-06-24 04:35PM
Dec-05-24 04:30PM
Dec-04-24 04:47PM
Nov-21-24 04:30PM
Nov-12-24 11:01PM
Nov-07-24 04:30PM
Nov-04-24 09:00AM
Oct-24-24 09:00AM
Oct-21-24 10:53AM
Oct-17-24 09:45AM
Oct-12-24 02:31PM
Oct-07-24 09:10PM
Oct-05-24 07:15AM
Oct-03-24 09:05AM
Oct-01-24 04:30PM
Sep-26-24 04:08PM
02:36PM
08:25AM
Sep-25-24 08:00PM
04:13PM
11:27AM
Jan-01-01 12:00AM
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.